What we are studying
This study will use an experimental drug called benralizumab to treat moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). “Experimental” means that the drug has not been approved by any Authority that regulates new medicines, including the US Food and Drug Administration (FDA).You have been asked to consider taking part in this study because you have been diagnosed with moderate, severe or very severe COPD that is not well controlled. This study is being carried out to evaluate benralizumab (study drug) as a treatment for moderate to very severe COPD compared with placebo (an inactive substance). COPD is a general term that includes chronic bronchitis (swelling and irritation in the airways) and emphysema (destruction of the air sacs and the walls separating the air sacs so that they become floppy and less able to transport oxygen). This results in symptoms such as cough, shortness of breath, chest tightness and sputum production. COPD is generally a progressive disease that gets worse over time and is associated with flare-ups also called exacerbations. This study will explore in what dose benralizumab needs to be given, who responds best to benralizumab, and how well benralizumab is tolerated. This study will measure levels of benralizumab in the blood and see how the body accepts the study drug.
If you complete all the scheduled study visits, you will be paid $1000.00. If you withdraw for any reason before completion of the study you will be paid $50.00 for each completed visit.